Novartis settles Sun Pharma suit, winning 7-month reprieve from generic Gleevec

Save

After nearly a year of fighting to protect the patent on its blockbuster leukemia drug Gleevec, Novartis has made peace with Indian drugmaker Sun Pharma, reaching a settlement that will keep Sun&#39;s generic version off the U.S. market until February 2016, <em>Reuters</em> reports. Novartis&#39; U.S. patent expires in July 2015.